The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Furthering cell therapy ambition across oncology and autoimmune diseases
Subscribe To Our Newsletter & Stay Updated
